Shares

2 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q4 2017

Feb 14, 2018

SELL
$6.68 - $8.74 $138,342 - $181,005
-20,710 Closed
0 $0
Q3 2017

Nov 14, 2017

BUY
$4.93 - $8.93 $102,100 - $184,940
20,710
20,710 $170,000

Others Institutions Holding ADAP

About Adaptimmune Therapeutics PLC


  • Ticker ADAP
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 163,370,000
  • Market Cap $98M
  • Description
  • Adaptimmune Therapeutics plc, a clinical-stage biopharmaceutical company, focuses on providing novel cell therapies primarily to patients with solid tumors in the United States and the United Kingdom. The company's specific peptide enhanced affinity receptor (SPEAR) T-cell platform enables it to identify cancer targets. It is developing ADP-A2M4...
More about ADAP
Track This Portfolio

Track Telemetry Investments, L.L.C. Portfolio

Follow Telemetry Investments, L.L.C. and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Telemetry Investments, L.L.C., based on Form 13F filings with the SEC.

News

Stay updated on Telemetry Investments, L.L.C. with notifications on news.